INSY Pengajuan SEC - Insys Therapeutics Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1516479

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Insys Therapeutics Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

February 11, 2020	8-K	Other Events 8-K 1 insy-8k20200211.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2020 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdict
February 11, 2020	15-12B	INSY / Insys Therapeutics Inc. 15-12B - - 15-12B 15-12B 1 d884224d1512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35902 INSYS THERAPEUTICS, INC. (Exact
February 10, 2020	EX-99.1	united states bankruptcy court district of DELAWARE Exhibit 99.1 united states bankruptcy court district of DELAWARE In re: Case No. 19-11292 (KG) Insys Therapeutics, Inc.; et al. Reporting Period: November 1 – November 30, 2019 Debtors MONTHLY OPERATING REPORT Reporting Period: November 1, 2019 – November 30, 2019 REQUIRED DOCUMENTS Form No. Document Attached Explanation Attached Affidavit/ Supplement Attached Schedule of Cash Receipts and Disburs
February 10, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2020 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commissi
February 5, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2020 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commissi
February 5, 2020	EX-2.1	Second Amendment to Transition Services Agreement, dated as of January 30, 2020, by and between Benuvia Therapeutics Inc. and Insys Therapeutics, Inc. Exhibit 2.1 EXECUTION VERSION SECOND AMENDMENT TO TRANSITION SERVICES AGREEMENT THIS SECOND AMENDMENT TO TRANSITION SERVICES AGREEMENT (this “Amendment”), dated as of January 30, 2020, is entered into by and between Benuvia Therapeutics Inc. (formerly known as Chilion Group Holdings US, Inc.), a Delaware corporation (“Buyer”), and Insys Therapeutics, Inc., a Delaware corporation (“Seller”). Buyer
January 17, 2020	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2020 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commissi
January 10, 2020	EX-99.1	UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE -x : In re:Chapter 11 : INSYS THERAPEUTICS, INC., et al., :Case No. 19-11292 (KG) : Debtors.1:Jointly Administered : :Re: D.I. 955 -x NOTICE OF FILING OF SECOND PLAN SUPPLEMENT PURSUANT TO THE SECOND AMENDED JOINT CHAPTER 11 PLAN OF LIQUIDATION OF INSYS THERAPEUTICS, INC. AND ITS AFFILIATED DEBTORS PLEASE TAKE NOTICE that on December
January 10, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 insy-8k20200106.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2020 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdictio
January 6, 2020	EX-2.1	Amendment to Transition Services Agreement, dated as of December 30, 2019, by and between Benuvia Therapeutics Inc. and Insys Therapeutics, Inc. Exhibit 2.1 EXECUTION VERSION AMENDMENT TO TRANSITION SERVICES AGREEMENT THIS AMENDMENT TO TRANSITION SERVICES AGREEMENT (this Amendment), dated as of December 30, 2019, is entered into by and between Benuvia Therapeutics Inc. (formerly known as Chilion Group Holdings US, Inc.), a Delaware corporation (“Buyer”), and Insys Therapeutics, Inc., a Delaware corporation (“Seller”). Buyer and Seller are
January 6, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commiss
January 6, 2020	EX-99.1	UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE -x : In re:Chapter 11 : INSYS THERAPEUTICS, INC., et al., :Case No. 19-11292 (KG) : Debtors.1:Jointly Administered : :Re: D.I. 955 -x NOTICE OF FILING OF PLAN SUPPLEMENT PURSUANT TO THE SECOND AMENDED JOINT CHAPTER 11 PLAN OF REORGANIZATION OF INSYS THERAPEUTICS, INC. AND ITS AFFILIATED DEBTORS PLEASE TAKE NOTICE that on December 4,
January 3, 2020	S-8 POS	INSY / Insys Therapeutics Inc. S-8 POS - - S-8 POS S-8 POS 1 insy-s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 3, 2020 Registration No. 333-223084 Registration No. 333-210064 Registration No. 333-202472 Registration No. 333-194374 Registration No. 333-188306 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NOS. 333-223084 3
January 3, 2020	S-8 POS	INSY / Insys Therapeutics Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 3, 2020 Registration No.
January 3, 2020	S-8 POS	INSY / Insys Therapeutics Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 3, 2020 Registration No.
January 3, 2020	S-8 POS	INSY / Insys Therapeutics Inc. S-8 POS - - S-8 POS S-8 POS 1 insy-s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 3, 2020 Registration No. 333-223084 Registration No. 333-210064 Registration No. 333-202472 Registration No. 333-194374 Registration No. 333-188306 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NOS. 333-223084 3
January 3, 2020	S-8 POS	INSY / Insys Therapeutics Inc. S-8 POS - - S-8 POS S-8 POS 1 insy-s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 3, 2020 Registration No. 333-223084 Registration No. 333-210064 Registration No. 333-202472 Registration No. 333-194374 Registration No. 333-188306 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NOS. 333-223084 3
December 26, 2019	EX-99.1	united states bankruptcy court district of DELAWARE EX-99.1 2 insy-ex9916.htm EX-99.1 Exhibit 99.1 united states bankruptcy court district of DELAWARE In re: Case No. 19-11292 (KG) Insys Therapeutics, Inc.; et al. Reporting Period: October 1 – October 31, 2019 Debtors MONTHLY OPERATING REPORT Reporting Period: October 1, 2019 – October 31, 2019 REQUIRED DOCUMENTS Form No. Document Attached Explanation Attached Affidavit/ Supplement Attached Schedul
December 26, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commiss
December 3, 2019	EX-2.1	Asset Purchase Agreement, dated as of December 2, 2019, by and between Renaissance Lakewood, LLC and Insys Therapeutics, Inc. EX-2.1 2 insy-ex219.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT BETWEEN RENAISSANCE LAKEWOOD, LLC AND INSYS THERAPEUTICS, INC. DATED AS OF DECEMBER 2, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 4 Section 1.1 Definitions4 Section 1.2 Interpretation10 Section 1.3 Currency10 ARTICLE II SALE AND PURCHASE OF TRANSFERRED ASSETS 10 Section 2.1 Purchase and Sale10 Section 2.2
December 3, 2019	EX-16.1	Letter from BDO USA, LLP, dated December 3, 2019 Exhibit 16.1 December 3, 2019 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Insys Therapeutics, Inc. Commission File Number 001-35902 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on November 26, 2019, to be filed by our former client, Insys Therapeutics, Inc. We agree with the statements made in response t
December 3, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 insy-8k20191126.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdict
December 3, 2019	EX-99.1	UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE -x : In re:Chapter 11 : INSYS THERAPEUTICS, INC., et al., :Case No. 19-11292 (KG) : Debtors.1:Jointly Administered : -x SECOND AMENDED JOINT CHAPTER 11 PLAN OF LIQUIDATION OF INSYS THERAPEUTICS, INC. AND ITS AFFILIATED DEBTORS WEIL, GOTSHAL & MANGES LLP Gary T. Holtzer (admitted pro hac vice) Ronit J. Berkovich (admitted pro hac vice
December 3, 2019	EX-99.2	UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE EX-99.2 5 insy-ex9927.htm EX-99.2 Exhibit 99.2 THIS PROPOSED DISCLOSURE STATEMENT IS NOT A SOLICITATION OF VOTES ON THE PLAN. ACCEPTANCES AND REJECTIONS OF THE PLAN MAY NOT BE SOLICITED UNTIL A DISCLOSURE STATEMENT HAS BEEN APPROVED BY THE BANKRUPTCY COURT. THE DEBTORS RESERVE THE RIGHT TO AMEND, SUPPLEMENT, OR OTHERWISE MODIFY THIS DISCLOSURE STATEMENT. UNITED STATES BANKRUPTCY COURT DISTRICT OF
November 25, 2019	NT 10-Q	INSY / Insys Therapeutics Inc. NT 10-Q - - NT 10-Q NT 10-Q 1 insy-nt10q20190930.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition
November 20, 2019	EX-99.2	UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE Exhibit 99.2 THIS PROPOSED DISCLOSURE STATEMENT IS NOT A SOLICITATION OF VOTES ON THE PLAN. ACCEPTANCES AND REJECTIONS OF THE PLAN MAY NOT BE SOLICITED UNTIL A DISCLOSURE STATEMENT HAS BEEN APPROVED BY THE BANKRUPTCY COURT. THE DEBTORS RESERVE THE RIGHT TO AMEND, SUPPLEMENT, OR OTHERWISE MODIFY THIS DISCLOSURE STATEMENT. UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE -x : In re:Chapter 11 : I
November 20, 2019	EX-99.1	UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE -x : In re:Chapter 11 : INSYS THERAPEUTICS, INC., et al., :Case No. 19-11292 (KG) : Debtors.1:Jointly Administered : -x AMENDED JOINT CHAPTER 11 PLAN OF LIQUIDATION OF INSYS THERAPEUTICS, INC. AND ITS AFFILIATED DEBTORS2 WEIL, GOTSHAL & MANGES LLP Gary T. Holtzer (admitted pro hac vice) Ronit J. Berkovich (admitted pro hac vice) Cand
November 20, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 insy-8k20191114.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdict
November 19, 2019	SC 13G	INSY / Insys Therapeutics Inc. / ETF MANAGERS GROUP, LLC - SCHEDULE 13G Passive Investment SC 13G 1 sc13g1119etfinsystherap.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Insys Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 45824V209 (CUSIP Number) June 13, 2019 (Date of Event which Requires Filing of this Statemen
November 4, 2019	EX-2.1	Transition Services Agreement, dated as of October 31, 2019, by and between Chilion Group Holdings US, Inc. and Insys Therapeutics, Inc. EX-2.1 2 insy-ex216.htm EX-2.1 Exhibit 2.1 Execution Version TRANSITION SERVICES AGREEMENT This Transition Services Agreement (this “Agreement”) is made and entered into effective as of October 31, 2019 (the “Closing Date”), by and between Insys Therapeutics, Inc., a Delaware corporation (“Seller”), and Chilion Group Holdings US, Inc., a Delaware corporation (“Buyer”). Seller and Buyer may each be
November 4, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 insy-8k20191031.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 Insys Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001- 35902 51-0327886 (State or other jurisdict
November 4, 2019	EX-99.1	united states bankruptcy court district of DELAWARE EX-99.1 3 insy-ex9917.htm EX-99.1 Exhibit 99.1 united states bankruptcy court district of DELAWARE In re: Case No. 19-11292 (KG) Insys Therapeutics, Inc.; et al. Reporting Period: September 1 – September 30, 2019 Debtors MONTHLY OPERATING REPORT Reporting Period: September 1, 2019 – September 30, 2019 REQUIRED DOCUMENTS Form No. Document Attached Explanation Attached Affidavit/ Supplement Attached
October 25, 2019	EX-2.1	Amendment No. 1 to Asset Purchase Agreement, dated as of October 23, 2019, by and between Chilion Group Holdings US, Inc. and Insys Therapeutics, Inc. Exhibit 2.1 EXECUTION VERSION AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this Amendment), dated as of October 23, 2019, is entered into by and between Chilion Group Holdings US, Inc., a Delaware corporation (“Buyer”)1, and Insys Therapeutics, Inc., a Delaware corporation (“Seller”). Buyer and Seller are each referred to individually as a “Party” a
October 25, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 insy-8k20191023.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 Insys Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001- 35902 51-0327886 (State or other jurisdict
October 2, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 insy-8k20190930.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdic
October 2, 2019	EX-99.1	united states bankruptcy court district of DELAWARE EX-99.1 2 insy-ex9916.htm EX-99.1 Exhibit 99.1 united states bankruptcy court district of DELAWARE In re:Case No. 19-11292 (KG) Insys Therapeutics, Inc.; et al. Reporting Period: August 1 – August 31, 2019 Debtors MONTHLY OPERATING REPORT Reporting Period: August 1, 2019 – August 31, 2019 REQUIRED DOCUMENTS Form No. Document Attached Explanation Attached Affidavit/ Supplement Attached Schedule of
September 27, 2019	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 insy-8k20190926.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2019 Insys Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001- 35902 51-0327886 (State or other jurisdi
September 26, 2019	8-K	Financial Statements and Exhibits 8-K 1 insy-8k20190925.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2019 Insys Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001- 35902 51-0327886 (State or other jurisdi
September 26, 2019	EX-2.1	Asset Purchase Agreement, dated as of September 25, 2019, by and between Pharmbio Korea, Inc. and Insys Therapeutics, Inc. EX-2.1 2 insy-ex216.htm EX-2.1 Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT BETWEEN PHARMBIO KOREA, INC. AND INSYS THERAPEUTICS, INC. DATED AS OF SEPTEMBER 25, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions2 Section 1.2 Interpretation11 Section 1.3 Currency11 ARTICLE II SALE AND PURCHASE OF TRANSFERRED ASSETS 11 Section 2.1 Purchase and Sale11 Section 2.2 Tra
September 17, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 insy-8k20190917.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdic
September 17, 2019	EX-99.1	UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE -x : In re:Chapter 11 : INSYS THERAPEUTICS, INC., et al., :Case No. 19-11292 (KG) : Debtors.1:Jointly Administered : -x JOINT CHAPTER 11 PLAN OF LIQUIDATION OF INSYS THERAPEUTICS, INC. AND ITS AFFILIATED DEBTORS WEIL, GOTSHAL & MANGES LLP Gary T. Holtzer (admitted pro hac vice) Ronit J. Berkovich (admitted pro hac vice) Candace M. Ar
September 17, 2019	EX-99.2	UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE Exhibit 99.2 THIS PROPOSED DISCLOSURE STATEMENT IS NOT A SOLICITATION OF VOTES ON THE PLAN. ACCEPTANCES AND REJECTIONS OF THE PLAN MAY NOT BE SOLICITED UNTIL A DISCLOSURE STATEMENT HAS BEEN APPROVED BY THE BANKRUPTCY COURT. THE DEBTORS RESERVE THE RIGHT TO AMEND, SUPPLEMENT, OR OTHERWISE MODIFY THIS DISCLOSURE STATEMENT PRIOR TO THE DISCLOSURE STATEMENT HEARING. UNITED STATES BANKRUPTCY COURT DIST
September 9, 2019	EX-99.1	united states bankruptcy court district of DELAWARE Exhibit 99.1 united states bankruptcy court district of DELAWARE In re:Case No. 19-11292 (KG) Insys Therapeutics, Inc.; et al. Reporting Period: July 1 – July 31, 2019 Debtors MONTHLY OPERATING REPORT Reporting Period: July 1, 2019 – July 31, 2019 REQUIRED DOCUMENTS Form No. Document Attached Explanation Attached Affidavit/ Supplement Attached Schedule of Cash Receipts and Disbursements MOR-1 X Ba
September 9, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commiss
September 3, 2019	EX-2.1	Asset Purchase Agreement, dated as of September 1, 2019, by and between BTcP Pharma, LLC and Insys Therapeutics, Inc. Exhibit 2.1 ASSET PURCHASE AGREEMENT BETWEEN BTcP PHARMA, LLC, AND INSYS THERAPEUTICS, INC. DATED AS OF September 1, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions2 Section 1.2 Interpretation16 Section 1.3 Currency16 ARTICLE II SALE AND PURCHASE OF TRANSFERRED ASSETS 16 Section 2.1 Purchase and Sale16 Section 2.2 Transferred Assets and Excluded Assets16 Section 2.3 Ass
September 3, 2019	8-K	Financial Statements and Exhibits 8-K 1 insy-8k20190901.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2019 Insys Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001- 35902 51-0327886 (State or other jurisdic
August 29, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2019 Insys Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001- 35902 51-0327886 (State or other jurisdiction of incorporation) (Commissi
August 13, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commission
August 13, 2019	EX-99.1	united states bankruptcy court district of DELAWARE Exhibit 99.1 united states bankruptcy court district of DELAWARE In re:Case No. 19-11292 (KG) Insys Therapeutics, Inc.; et al. Reporting Period: June 10 – June 30, 2019 Debtors MONTHLY OPERATING REPORT Reporting Period: June 10, 2019 – June 30, 2019 REQUIRED DOCUMENTS Form No. Document Attached Explanation Attached Affidavit/ Supplement Attached Schedule of Cash Receipts and Disbursements MOR-1 X
August 8, 2019	NT 10-Q	INSY / Insys Therapeutics Inc. NT 10-Q - - NT 10-Q NT 10-Q 1 insy-nt10q20190630.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Repor
August 8, 2019	EX-2.1	Asset Purchase Agreement, dated as of August 5, 2019, by and between Hikma Pharmaceuticals USA Inc. and Insys Therapeutics, Inc. Exhibit 2.1 ASSET PURCHASE AGREEMENT BETWEEN HIKMA PHARMACEUTICALS USA INC. AND INSYS THERAPEUTICS, INC. DATED AS OF AUGUST 5, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions2 Section 1.2 Interpretation11 Section 1.3 Currency11 ARTICLE II SALE AND PURCHASE OF TRANSFERRED ASSETS 11 Section 2.1 Purchase and Sale11 Section 2.2 Transferred Assets and Excluded Assets12 Secti
August 8, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 insy-8k20190805.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction
August 8, 2019	EX-2.2	Asset Purchase Agreement, dated as of August 6, 2019, by and between Chilion Group Holdings US, Inc. and Insys Therapeutics, Inc. Exhibit 2.2 ASSET PURCHASE AGREEMENT BETWEEN CHILION GROUP HOLDINGS US, INC. AND INSYS THERAPEUTICS, INC. DATED AS OF AUGUST 6, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions2 Section 1.2 Interpretation12 Section 1.3 Currency12 ARTICLE II SALE AND PURCHASE OF TRANSFERRED ASSETS 12 Section 2.1 Purchase and Sale12 Section 2.2 Transferred Assets and Excluded Assets12 Sect
August 8, 2019	EX-99.1	2 EX-99.1 4 insy-ex9916.htm EX-99.1 Exhibit 99.1 An investment in the Company’s (as defined below) securities involves a high degree of risk. You should carefully consider the risk factors described below in evaluating the Company’s (as defined below) future prospects. In particular, keep these risk factors in mind when you read “forward-looking” statements in the Company’s various reports filed wit
July 19, 2019	EX-99.1	IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Insys Therapeutics, Inc. et al Debtors. : : : : : : Chapter 11 Case No. 19-11292 (KG) Jointly Administered INITIAL MONTHLY OPERATING REPORT File report and attachments with Court and submit copy to United States Trustee within 15 days after order for relief. Certificates of insurance must name United States Trus
July 19, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commission
July 15, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 insy-8k20190709.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction o
June 11, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commission
June 10, 2019	EX-99	INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code Operations to Exhibit 99.1 INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code Operations to Continue as Normal Including Payment of Employee Wages and Benefits and Continuing Programs for Customers; Vendors and Suppliers to Rece
June 10, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Bankruptcy or Receivership 8-K 1 insy-8k20190609.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction
June 7, 2019	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorpor
June 6, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commission F
May 24, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commission F
May 13, 2019	10-Q	INSY / Insys Therapeutics Inc. 10-Q Quarterly Report 10-Q Table of Contents FYI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 13, 2019	EX-10.1	Amendment to Manufacturing and Supply Agreement, dated as of February 26, 2019, by and between the Registrant and Renaissance (filed herewith) Exhibit 10.1 Amendment No. 6 to Manufacturing Agreement and Consent This AMENDMENT NO. 6 (“Amendment No. 6”) to the Manufacturing Agreement (as defined below) is effective on the 26th day of February 2019. BETWEEN: 1. INSYS MANUFACTURING, LLC, a company organized and existing under the laws of the State of Texas, with a place of business at 1333 S. Spectrum Blvd., Suite 100, Chandler, AZ 85286 (he
May 11, 2019	NT 10-Q	INSY / Insys Therapeutics Inc. NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo
May 11, 2019	EX-99.1	INSYS Therapeutics Reports First Quarter 2019 Results Company Continues to Execute Against Pipeline-Focused Strategy New Drug Application Submitted for Proprietary Naloxone Nasal Spray Formulation Company Provides Liquidity Update EX-99.1 2 insy-ex99110.htm EX-99.1 Exhibit 99.1 NEWS RELEASE INSYS Therapeutics Reports First Quarter 2019 Results Company Continues to Execute Against Pipeline-Focused Strategy New Drug Application Submitted for Proprietary Naloxone Nasal Spray Formulation Company Provides Liquidity Update PHOENIX—May 10, 2019—INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and c
May 11, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 insy-8k20190331.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction o
April 30, 2019	10-K/A	INSY / Insys Therapeutics Inc. 10-K/A Annual Report 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-
April 29, 2019	SC 13G/A	INSY / Insys Therapeutics Inc. / ETF MANAGERS GROUP, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Insys Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 45824V209 (CUSIP Number) April 26, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru
April 23, 2019	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K/A 1 insy-8ka20190414.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2019 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (St
April 23, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2019 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commission
April 18, 2019	EX-99.1	INSYS Therapeutics Implements Leadership Changes Andrew G. Long Appointed Chief Executive Officer Exhibit 99.1 INSYS Therapeutics Implements Leadership Changes Andrew G. Long Appointed Chief Executive Officer PHOENIX – April 15, 2019 – INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effe
April 18, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 insy-8k20190414.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2019 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction
March 13, 2019	10-K	INSY / Insys Therapeutics Inc. 10-K (Annual Report) 10-K 1 insy-10k20181231.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
March 13, 2019	EX-21.1	Subsidiaries of the Registrant EX-21.1 2 insy-ex21133.htm EX-21.1 Exhibit 21.1 Subsidiaries of Insys Therapeutics, Inc.: NAME: JURISDICTION OF ORGANIZATION: Insys Pharma, Inc. Delaware Insys Development Company, Inc. Delaware Insys Manufacturing, LLC Texas IPSC, LLC Arizona IC Operations, LLC Delaware
March 7, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 insy-8k20190307.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2019 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction
March 7, 2019	EX-99.1	INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results Strategic Transformation Building Momentum with Two Planned NDAs in 2019 EX-99.1 2 insy-ex9916.htm EX-99.1 Exhibit 99.1 NEWS RELEASE INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results Strategic Transformation Building Momentum with Two Planned NDAs in 2019 PHOENIX—Mar. 7, 2019—INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported finan
March 7, 2019	SC 13G/A	INSY / Insys Therapeutics Inc. / ETF MANAGERS GROUP, LLC - SC 13G/A Passive Investment SC 13G/A 1 s116606sch13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Insys Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 45824V209 (CUSIP Number) March 6, 2019 (Date of Event which Requires Filing of this Statement) Check t
February 26, 2019	SC 13G/A	INSY / Insys Therapeutics Inc. / ETF MANAGERS GROUP, LLC - SC 13G/A Passive Investment SC 13G/A 1 s116340sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Insys Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 45824V209 (CUSIP Number) February 25, 2019 (Date of Event which Requires Filing of this Statement) Chec
February 19, 2019	SC 13G	INSY / Insys Therapeutics Inc. / ETF MANAGERS GROUP, LLC - SC 13G Passive Investment SC 13G 1 s116215sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Insys Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 45824V209 (CUSIP Number) February 15, 2019 (Date of Event which Requires Filing of this Statement) Check the
February 13, 2019	SC 13G/A	INSY / Insys Therapeutics Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G HOLDINGS REPORT AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
November 9, 2018	10-Q	INSY / Insys Therapeutics Inc. 10-Q (Quarterly Report) 10-Q 1 insy-10q20180930.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per
November 5, 2018	EX-99.1	INSYS Therapeutics Reports Third Quarter 2018 Results Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials EX-99.1 2 insy-ex99120.htm EX-99.1 Exhibit 99.1 NEWS RELEASE INSYS Therapeutics Reports Third Quarter 2018 Results Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials PHOENIX—Nov. 5, 2018—INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical
November 5, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2018 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commissi
October 10, 2018	EX-10.1	Executive Employment Agreement, dated as of October 10, 2018, by and between the Registrant and Mark Nance (24) Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of October 10, 2018, (the “Effective Date”), by and among Insys Therapeutics, Inc. (the “Company”) and Mark E. Nance (“Executive”) (the Company and Executive, collectively, the “Parties”). WITNESSETH: WHEREAS, Executive is currently employed by the Company as its Chief Legal Officer and Gener
October 10, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2018 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commissi
October 10, 2018	EX-99.1	INSYS Therapeutics Names New General Counsel Exhibit 99.1 NEWS RELEASE INSYS Therapeutics Names New General Counsel PHOENIX—Oct. 10, 2018—INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the addition of Mark Nance to its senior management team as chief legal officer and general counsel. “As we continue to transform the
August 9, 2018	10-Q	INSY / Insys Therapeutics Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00
August 8, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 insy-8k20180630.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2018 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction
August 8, 2018	EX-99.1	INSYS Therapeutics Reports Second Quarter 2018 Results Focus remains on advancing pipeline across cannabinoid and spray platforms Exhibit 99.1 NEWS RELEASE INSYS Therapeutics Reports Second Quarter 2018 Results Focus remains on advancing pipeline across cannabinoid and spray platforms PHOENIX—Aug. 8, 2018—INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids (CBD) and spray technology, today reported financial results for its second quarter ende
May 10, 2018	EX-10.3	Amendment to Manufacturing and Supply Agreement, dated as of April 10, 2018 by and between the Registrant and Renaissance (27) Exhibit 10.3 Amendment No. 5 to Manufacturing Agreement THIS Amendment No. 5 (“Amendment No. 5”) to the Manufacturing Agreement (as defined below) is effective on the th day of April 2018, BETWEEN: 1. INSYS MANUFACTURING, LLC, a company organized under the laws of the State of Texas, with a place of business at 1333 S. Spectrum Blvd., Suite 100, Chandler, AZ 85286 (hereinafter referred to as “COMP
May 10, 2018	10-Q	INSY / Insys Therapeutics Inc. 10-Q (Quarterly Report) 10-Q 1 insy-10q20180331.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period
May 1, 2018	DEFA14A	INSY / Insys Therapeutics Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant☒ Filed by a Party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy Stateme
April 16, 2018	DEF 14A	INSY / Insys Therapeutics Inc. DEF 14A DEF 14A 1 insy-def14a20171231.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant☒ Filed by a Party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RU
April 2, 2018	EX-99.1	INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors Exhibit 99.1 NEWS RELEASE INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors PHOENIX—April 2, 2018—INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Trudy Vanhove as a new independent member of its Board of Directors. Given her extensive experie
April 2, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 insy-8k20180402.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2018 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction
March 12, 2018	EX-10.19	Executive Employment Agreement, dated as of August 7, 2017, by and between the Registrant and Andrew Long (23) Exhibit 10.19 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of August 7, 2017, (the “Effective Date”), by and among Insys Therapeutics, Inc. (the “Company”) and Andrew Long (“Executive”) (the Company and Executive, collectively, the “Parties”). WITNESSETH: WHEREAS, Executive is currently employed by the Company as its Executive Vice President and Chi
March 12, 2018	10-K	INSY / Insys Therapeutics Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35
March 8, 2018	SC 13D	INSY / Insys Therapeutics Inc. / Insys Therapeutics, Inc. Voting Trust - SCHEDULE 13D Activist Investment SC 13D 1 i23988949a.htm SCHEDULE 13D CUSIP No. 45824V209 Page 1 of 6 Pages SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Insys Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 Par Value Per Share (Title of Class of Securities) 45824V209 (CUSIP Number) Insys Therapeutics, Inc. Voti
March 8, 2018	EX-99.1	VOTING TRUST AGREEMENT RELATING TO SHARES OF INSYS THERAPEUTICS, INC. Dated as of: February 27, 2018 TABLE OF CONTENTS EX-99.1 2 i23988949b.htm VOTING TRUST AGREEMENT VOTING TRUST AGREEMENT RELATING TO SHARES OF INSYS THERAPEUTICS, INC. Dated as of: February 27, 2018 TABLE OF CONTENTS Page ARTICLE I Defined Terms 1 SECTION 1.01. Definitions 1 SECTION 1.02. Rules of Construction 6 ARTICLE II Deposit of Equity Interests 6 SECTION 2.01. Initial Deposit of Equity Interests 6 SECTION 2.02. Additional Deposits of Equity
March 1, 2018	EX-10.2	Registration Rights Agreement among Insys Therapeutics, Inc., Dr. John N. Kapoor and certain beneficiaries (26) EX-10.2 3 insy-ex1026.htm EX-10.2 Exhibit 10.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT among insys therapeutics, inc. john n. kapoor the john n. kapoor trust, dated september 20, 1989 and ej financial/neo management, l.p. Dated as of February 28, 2018 TABLE OF CONTENTS Page ARTICLE I General Provisions SECTION 1.01. Defined Terms 1 SECTION 1.02. Other Definitional Provisions 5 ARTICLE II R
March 1, 2018	EX-10.1	Voting Trust Agreement by and among Insys Therapeutics, Inc., Dr. John N. Kapoor, Bessemer Trust Company of Delaware, N.A., as the initial trustee thereunder and certain other specified beneficiaries (25) insy-ex1017.htm Exhibit 10.1 EXECUTED VERSION VOTING TRUST AGREEMENT RELATING TO SHARES OF INSYS THERAPEUTICS, INC. Dated as of: February 27, 2018 Table of Contents Page ARTICLE I Defined Terms 1 SECTION 1.01. Definitions 1 SECTION 1.02. Rules of Construction 6 ARTICLE II Deposit of Equity Interests 6 SECTION 2.01. Initial Deposit of Equity Interests 6 SECTION 2.02. Additional Deposits of Equity I
March 1, 2018	8-K	Financial Statements and Exhibits 8-K 1 insy-8k20180227.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or other jurisdict
February 16, 2018	S-8	INSY / Insys Therapeutics Inc. S-8 insy-s8.htm As filed with the Securities and Exchange Commission on February 16, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 51-0327886 (State or other jurisdiction of incorporation or organi
February 13, 2018	SC 13G/A	INSY / Insys Therapeutics Inc. / ORBIMED ADVISORS LLC - 13G/A Passive Investment SC 13G/A 1 insy123117a2.htm 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Insys Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45824V209 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 1, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2018 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commissi
February 1, 2018	EX-99.1	INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors insy-ex99117.htm Exhibit 99.1 NEWS RELEASE INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors PHOENIX?Feb. 1, 2018?INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Vaseem Mahboob as a new independent member of its board of directors. A former
November 4, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commissi
November 4, 2017	EX-99.1	INSY 3Q17 Earnings Call CEO / CFO Script insy-ex9916.htm Exhibit 99.1 INSY 3Q17 Earnings Call CEO / CFO Script OPERATOR: Good morning, ladies and gentlemen, and welcome to the INSYS Therapeutics Third Quarter 2017 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the call over to Jackie Marcus at the Alpha IR Group. Please go ahead, Jackie. Alpha IR [SLIDE 2] Thank you, [Op
November 3, 2017	10-Q	INSY / Insys Therapeutics Inc. 10-Q (Quarterly Report) 10-Q 1 insy-10q20170930.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per
November 3, 2017	EX-10.1	Executive Employment Agreement, dated as of April 17, 2017, by and between the Registrant and Saeed Motahari (21) Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of April 17, 2017 (the “Effective Date”), by and among Insys Therapeutics, Inc. (the “Company”) and Saeed Motahari (“Executive”) (the Company and Executive, collectively, the “Parties”). WITNESSETH: WHEREAS, Executive is currently employed by the Company as its President and Chief Executive O
November 2, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commissi
November 2, 2017	EX-99.1	Insys Therapeutics Reports Third Quarter 2017 Results Official Launch of SYNDROS® and Filing NDA for Buprenorphine Sublingual Spray Drive Progress on Strategic Initiatives insy-ex9916.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Third Quarter 2017 Results Official Launch of SYNDROS? and Filing NDA for Buprenorphine Sublingual Spray Drive Progress on Strategic Initiatives PHOENIX?Nov. 2, 2017?INSYS Therapeutics, Inc. (NASDAQ: INSY) (?INSYS? or ?the company?), today reported financial results for its third quarter ended Sept. 30, 2017. OVERALL HIG
October 30, 2017	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2017 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commissi
August 11, 2017	CORRESP	Insys Therapeutics ESP CORRESP 1 filename1.htm Insys Therapeutics, Inc. 1333 S. Spectrum Blvd, Suite 100 Chandler, Arizona 85286 August 11, 2017 VIA EDGAR Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Re: Insys Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2016 Filed April 3, 2017 File N
August 7, 2017	10-Q	INSY / Insys Therapeutics Inc. 10-Q (Quarterly Report) 10-Q 1 insy-10q20170630.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f
August 7, 2017	EX-10.1	Amendment to Restated Supply, Development & Exclusive Licensing Agreement dated as of April 6, 2017, by and between the Registrant and AptarGroup, Inc. (20) Exhibit 10.1 AMENDMENT NUMBER ONE TO THE AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENT THIS AMENDMENT NUMBER ONE (“Amendment Number 1”) to the AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENT with an effective date of October 30, 2015 (the “A&R Agreement”), is hereby entered into as of April 6, 2017 with an effective date of January 1, 2017 (“Effe
August 3, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition insy-8k20170803.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2017 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorp
August 3, 2017	EX-99.1	Insys Therapeutics Reports Second Quarter 2017 Results insy-ex9916.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Second Quarter 2017 Results PHOENIX, Ariz. ? August 3, 2017? Insys Therapeutics, Inc. (NASDAQ: INSY) ("INSYS" or "the Company") today announced financial results for the three-month period ended June 30, 2017. Highlights of and subsequent to the second quarter of 2017 include: ? Total net revenue was $42.6 million, compa
July 19, 2017	EX-99.1	Insys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer insy-ex9916.htm Exhibit 99.1 Insys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer PHOENIX, July 18, 2017 (GLOBE NEWSWIRE) - Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) announced today that Andrew G. Long has joined the company as Chief Financial Officer, effective August 7, 2017. Andrew G. Long is a seasoned finance executive with three decades of exper
July 19, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2017 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commission
May 16, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits insy-8k20170516.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2017 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorpor
May 16, 2017	EX-99.1	Insys Therapeutics Announces Chief Financial Officer Transition insy-ex9917.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Announces Chief Financial Officer Transition PHOENIX, Ariz. ? May 16, 2017 ? Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that Darryl S. Baker, the Company's Chief Financial Officer (?CFO?), will transition from the role of CFO when a successor is hired. Insys has engaged an executive search
May 9, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 Insys Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporation) (Commission Fi
May 9, 2017	EX-99.1	Insys Therapeutics Reports First Quarter 2017 Results insy-ex9916.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports First Quarter 2017 Results PHOENIX, Ariz. ? May 9, 2017 ? Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended March 31, 2017. Highlights of and subsequent to the first quarter of 2017 include: ? Net revenue totaled $36.0 million, compared t
May 9, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35902 Insys The
May 8, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders insy-8k20170502.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2017 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorpora
May 8, 2017	EX-99.1	Insys Therapeutics, Inc. Appoints Rohit Vishnoi to Board of Directors insy-ex9916.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Insys Therapeutics, Inc. Appoints Rohit Vishnoi to Board of Directors PHOENIX, Ariz - May 4, 2017 - Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced that Rohit Vishnoi, a seasoned healthcare executive, has been appointed to the Company?s Board of Directors, effective as of May 2, 2017. Mr. Vishnoi has also been appointed
April 17, 2017	DEF 14A	Insys Therapeutics DEF 14A DEF 14A 1 insy-def14a20160503.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant☒ Filed by a Party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RU
April 14, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers insy-8k20170411.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2017 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission F
April 7, 2017	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) 10-Q/A 1 d368363d10qa.htm 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the
April 7, 2017	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi
April 7, 2017	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 3, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2017 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commission
April 3, 2017	EX-99.1	Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results EX-99.1 Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results PHOENIX, Ariz. ? April 3, 2017 ? Insys Therapeutics, Inc. (NASDAQ: INSY) (?Insys? or ?the Company?) today announced financial results for the three- and twelve-month periods ended December 31, 2016. Highlights of and subsequent to the fourth quarter of 2016 include: ? Total net revenue de
April 3, 2017	EX-21.1	Subsidiaries of the Registrant (25) Exhibit 21.1 Subsidiaries of Insys Therapeutics, Inc.: NAME: JURISDICTION OF ORGANIZATION: Insys Pharma, Inc. Delaware Insys Development Company, Inc. Delaware Insys Manufacturing, LLC Texas IPSC, LLC Arizona
April 3, 2017	EX-10.17	Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Grant Agreement thereunder (19) Exhibit 10.18 Insys Therapeutics, Inc. Restricted Stock Unit Grant Notice (2013 Equity Incentive Plan) Insys Therapeutics, Inc. (the ?Company?), pursuant to Section 6(b) of the Company?s 2013 Equity Incentive Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?Award?).
April 3, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35902 Insys Therapeu
March 31, 2017	8-K	Regulation FD Disclosure, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2017 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commission
March 27, 2017	EX-99.1	Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017 EX-99.1 2 insy-ex9916.htm EX-99.1 Exhibit 99.1 Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017 PHOENIX, Ariz. — March 27, 2017 — Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief E
March 27, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2017 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission File No.) (IRS Employ
March 15, 2017	NT 10-K	Insys Therapeutics NT 10-K NT 10-K 1 insy-nt10k20161231.htm NT 10-K OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response 2.50 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2016 ☐ T
March 15, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2017 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commission
March 15, 2017	EX-99.1	-- Fourth Quarter 2016 Net Sales Estimated at $54 million -- insy-ex9916.htm Exhibit 99.1 Insys Therapeutics Announces Delay in the Release of its Fourth Quarter and Full Year 2016 Results - Fourth Quarter 2016 Net Sales Estimated at $54 million - PHOENIX, March 15, 2017 (GLOBE NEWSWIRE) - Insys Therapeutics, Inc. (NASDAQ:INSY) (?Insys? or ?the Company?) today announced that the Company will delay the release of its financial results for the fourth quarter
February 13, 2017	SC 13G/A	INSY / Insys Therapeutics Inc. / ORBIMED ADVISORS LLC - 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 10, 2017	EX-99.1	Dated: February 10, 2017 EX-99.1 2 e72970ex99-1.htm JOINT FILING AGREEMENT Exhibit 99.1 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of Amendment No. 2 to Schedule 13G (including additional amendments thereto) with respect to the shares of common stock, par value $0.01 per share, of Insys Therapeutics,
February 10, 2017	SC 13G/A	INSY / Insys Therapeutics Inc. / SCOPIA CAPITAL MANAGEMENT LP - FORM SC 13G/A Passive Investment SC 13G/A 1 e72970sc13g-a.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Insys Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 45824V209 (CUSIP Number) January 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the ap
January 12, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 insy201701128k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2017 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation
January 12, 2017	EX-99.1	Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board PHOENIX, AZ? January 9, 2017 - Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that Dr. John N. Kapoor, its Founder, President and Chief Executive
November 3, 2016	EX-99.1	Insys Therapeutics Reports Third Quarter 2016 Results EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Third Quarter 2016 Results PHOENIX, Ariz. — November 3, 2016— Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended September 30, 2016. Highlights of and subsequent to the third quarter of 2016 include: ● Total net revenue w
November 3, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 insy201611028k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisd
November 3, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q insy2016081810q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file
September 21, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits insy201609218k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of inc
September 21, 2016	EX-99.1	Insys Therapeutics Announces CEO Succession Plan ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Announces CEO Succession Plan PHOENIX, AZ? September 21, 2016 - Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that the Company?s Board of Directors (?Board?) has initiated a search to identify a candidate to succeed Dr. John N. Kapoor as President and Chief Executive Officer (?CEO?). Dr. Kapoor wi
August 16, 2016	144/A	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
August 16, 2016	144/A	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
August 16, 2016	144	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
August 16, 2016	144	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
August 11, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers insy201608108k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission F
August 9, 2016	144	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
August 9, 2016	144	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
August 5, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 insy2016063010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com
August 5, 2016	EX-10.1	Amendment to Manufacturing and Supply Agreement, dated as of July 14, 2016 by and between the Registrant and DPT Lakewood, LLC (18) Exhibit 10.1
August 3, 2016	EX-99.1	Insys Therapeutics Reports Second Quarter 2016 Results ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Second Quarter 2016 Results PHOENIX, Ariz. ? August 3, 2016? Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include: ? Total net revenue was $67.1 million, compared t
August 3, 2016	8-K	Insys Therapeutics FORM 8-K (Current Report/Significant Event) insy201608028k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorpo
July 21, 2016	CORRESP	Insys Therapeutics ESP CORRESP 1 filename1.htm Insys Therapeutics, Inc. 1333 S. Spectrum Blvd, Suite 100 Chandler, Arizona 85286 July 21, 2016 VIA EDGAR Mr. Jim B. Rosenberg, Senior Assistant Chief Accountant Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Re: Insys Therapeutics, Inc. Form 10-K for Fiscal Y
July 5, 2016	EX-99.1	Insys Therapeutics Announces FDA Approval of Syndros™ ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Announces FDA Approval of Syndros™ PHOENIX, July 05, 2016 (GLOBE NEWSWIRE) - Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys’ dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannab
July 5, 2016	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commission F
June 6, 2016	144	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
May 9, 2016	EX-3.1	Amended and Restated Bylaws of Insys Therapeutics, Inc. (2) EX-3.1 2 ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 AMended and restated BYLAWS OF INSYS THERAPEUTICS, Inc. ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as
May 9, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K 1 insy201605098k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdictio
May 5, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q insy2016033110q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num
April 28, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commission
April 28, 2016	EX-99.1	Insys Therapeutics Reports First Quarter 2016 Results ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports First Quarter 2016 Results PHOENIX, Ariz. — April 28, 2016— Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended March 31, 2016. Highlights of and subsequent to the first quarter of 2016 include: ● Total net revenue decreased to $62.0 million, co
April 20, 2016	DEF 14A	Insys Therapeutics FORM DEF 14A insy20160415def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant? Filed by a Party other than the Registrant? Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? D
April 11, 2016	EX-99.1	Insys Therapeutics Reports Preliminary Estimated Revenues from Subsys for the First Quarter 2016 ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Preliminary Estimated Revenues from Subsys for the First Quarter 2016 PHOENIX, AZ? April 11, 2016 - Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that its preliminary estimated revenues from Subsys? (fentanyl sublingual spray) for the first quarter of 2016 will be in the range of $61 milli
April 11, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 insy201604088k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdic
March 22, 2016	EX-99.1	Insys Therapeutics, Inc. Announces 3-Month Extension of PDUFA Date for Syndros EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Insys Therapeutics, Inc. Announces 3-Month Extension of PDUFA Date for Syndros PHOENIX, AZ – March 22, 2016 - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for SyndrosTM (dronabinol oral solution) from Ap
March 22, 2016	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commission
March 10, 2016	S-8	Insys Therapeutics FORM S-8 S-8 1 insy20160309s8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 10, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 51-0327886 (State or other jurisdiction of inco
March 10, 2016	SC 13G/A	INSY / Insys Therapeutics Inc. / SCOPIA CAPITAL MANAGEMENT LP - FORM SC 13G/A Passive Investment SC 13G/A 1 e68631sc13g-a.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Insys Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 45824V209 (CUSIP Number) February 29, 2016 (Date of Event Which Requires Filing of this Statement) Check the a
March 4, 2016	144	Insys Therapeutics FORM 144 144 1 form144.htm FORM 144 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.C. 20549 Expires: May 31, 2017 Estimated average burden FORM 144 hours per response 1.00 NOTICE OF PROPOSED SALE OF SECURITIES SEC USE ONLY PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 DOCUMENT SEQUENCE NO. CUSIP NUMBER ATTENTION: Transmit for filing 3 copies of thi
February 29, 2016	EX-10.12	Amended and Restated Supply, Development & Exclusive Licensing Agreement dated as of October 30, 2015 by and between the Registrant and AptarGroup, Inc. (22) Exhibit 10.12 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENT This AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENT (the ?Agreement?), effective as of October 30, 2015 (the ?Effective
February 29, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K insy2015123110k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-
February 29, 2016	EX-21.1	Subsidiaries of Insys Therapeutics, Inc.: Exhibit 21.1 Subsidiaries of Insys Therapeutics, Inc.: NAME: JURISDICTION OF ORGANIZATION: Insys Pharma, Inc. Delaware Insys Development Company, Inc. Delaware Insys Manufacturing, LLC Texas IPSC, LLC Arizona
February 23, 2016	EX-99.1	Insys Therapeutics Reports Fourth Quarter and Year End 2015 Results ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Fourth Quarter and Year End 2015 Results PHOENIX, Ariz. — February 23, 2016 — Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three- and twelve-month periods ended December 31, 2015. Highlights of and subsequent to the fourth quarter of 2015 include: ● Total net reve
February 23, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2016 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commiss
February 16, 2016	SC 13G	INSY / Insys Therapeutics Inc. / SCOPIA CAPITAL MANAGEMENT LP Passive Investment SC 13G 1 d704358913-g.htm STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Insys Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 45824V209 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
February 12, 2016	SC 13G	INSY / Insys Therapeutics Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment SC 13G 1 insy123115.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Insys Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45824V209 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
November 5, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 insy201511048k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2015 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisd
November 5, 2015	EX-99.2	Insys Therapeutics Announces Stock Repurchase Program EX-99.2 3 ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 For Immediate Release Insys Therapeutics Announces Stock Repurchase Program PHOENIX, AZ – November 5, 2015 - Insys Therapeutics, Inc. (Nasdaq: INSY) (“Insys” or “the Company”) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock. "The Board of Directors and management team believe t
November 5, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 insy2015093010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio
November 5, 2015	EX-10.1	Separation Agreement Exhibit 10.1 Separation Agreement This Separation Agreement ("Agreement") is entered into as of November 4, 2015 (the "Execution Date") by and between Insys Therapeutics, Inc., a Delaware corporation, ("Insys") on behalf of itself, its subsidiaries and other corporate affiliates and each of their respective employees, officers, directors, owners, shareholders and agents (collectively referred to h
November 5, 2015	EX-99.1	Insys Therapeutics Reports Record Third Quarter 2015 Results Announces Senior Management Changes and Appointments Announces Stock Repurchase up to $50 Million ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Record Third Quarter 2015 Results Announces Senior Management Changes and Appointments Announces Stock Repurchase up to $50 Million PHOENIX, AZ? November 5, 2015 - Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three- and nine-month periods ended September 30, 2015
November 5, 2015	EX-10.2	INSYS THERAPEUTICS, INC. (“COMPANY”) EMPLOYMENT OFFER STATEMENT AND AGREEMENT (“OFFER STATEMENT”) EX-10.2 3 ex10-2.htm EXHIBIT 10.2 EXHIBIT 10.2 INSYS THERAPEUTICS, INC. (“COMPANY”) EMPLOYMENT OFFER STATEMENT AND AGREEMENT (“OFFER STATEMENT”) TO: Dan Brennan “EFFECTIVE DATE”: October 20, 2015 STATUS: Salary, Exempt “EMPLOYMENT START DATE”: November 1, 2015 POSITION: Your title will be Executive Vice President and Chief Operating Officer (“COO”). During your employment, and excluding any period
September 14, 2015	144	Insys Therapeutics FORM 144 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
September 10, 2015	144	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
August 27, 2015	8-K	Other Events 8-K 1 insy201508278k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2015 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation
August 6, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 insy2015063010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil
August 6, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporation) (Commission
August 6, 2015	EX-10.1	Manufacturing Agreement dated as of May 24, 2011 by and between the Registrant and DPT Lakewood, LLC, as amended on October 29, 2013 and April 30, 2015 (13) Exhibit 10.1
August 6, 2015	EX-99.1	Insys Therapeutics Reports Second Quarter 2015 Results ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Second Quarter 2015 Results PHOENIX, AZ?August 6, 2015 - Insys Therapeutics, Inc. (Nasdaq: INSY) (?Insys? or ?the Company?) today announced financial results for the three- and six-month periods ended June 30, 2015. Highlights of and subsequent to the second quarter of 2015 include: ? Total net revenue increased to $77.6 mill
June 10, 2015	144	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
May 18, 2015	144	Insys Therapeutics FORM 144 Form 144: Notice of Proposed Sale of Securities UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
May 11, 2015	144	Insys Therapeutics FORM 144 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
May 11, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35902 Insys
May 7, 2015	EX-99.1	Insys Therapeutics Reports First Quarter 2015 Results ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports First Quarter 2015 Results PHOENIX, AZ?May 7, 2015 - Insys Therapeutics, Inc. (Nasdaq: INSY) ("Insys" or "the Company") today announced its financial results for the three-month period ended March 31, 2015. Highlights of and subsequent to the first quarter of 2015 include: ? Total net revenue increased to $70.8 million versus
May 7, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events insy201505068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2015 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State or other jurisdiction of incorporat
April 20, 2015	DEF 14A	Insys Therapeutics FORM DEF 14A DEF 14A 1 insy20150416def14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant☒ Filed by a Party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED B
March 5, 2015	144	Insys Therapeutics FORM 144 144 1 form144.htm FORM 144 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.C. 20549 Expires: May 31, 2017 Estimated average burden FORM 144 hours per response 1.00 NOTICE OF PROPOSED SALE OF SECURITIES SEC USE ONLY PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 DOCUMENT SEQUENCE NO. CUSIP NUMBER ATTENTION: Transmit for filing 3 copies of thi
March 3, 2015	EX-99.1	Insys Therapeutics Reports Fourth Quarter and Year End 2014 Results Record Quarterly Revenue of $66.5 Million Driven by Continued Growth in Subsys Net Revenue EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Fourth Quarter and Year End 2014 Results Record Quarterly Revenue of $66.5 Million Driven by Continued Growth in Subsys Net Revenue PHOENIX, AZ – March 3, 2015 - Insys Therapeutics, Inc. (Nasdaq: INSY) (“Insys” or “the Company”) today announced its financial results for the three- and twelve- month peri
March 3, 2015	S-8	INSY / Insys Therapeutics Inc. S-8 - - FORM S-8 S-8 1 insy20150227s8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 3, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 51-0327886 (State or other jurisdiction of incor
March 3, 2015	EX-10.1	CONSULTANT AGREEMENT BY AND BETWEEN INSYS THERAPEUTICS, INC. AND DR. JOHN KAPOOR ex10-1.htm Exhibit 10.1 CONSULTANT AGREEMENT BY AND BETWEEN INSYS THERAPEUTICS, INC. AND DR. JOHN KAPOOR STATUS: CONSULTANT START DATE: March 3, 2015 POSITION: Your position at the Company will be a consultant (non-employee) reporting to the Board of Directors (the “Board”). You are an independent contractor of the Company, and this Consultant Agreement shall not be construed to create any associa
March 3, 2015	EX-4.1	Form of Common Stock Certificate of Registrant (4) Exhibit 4.1
March 3, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35902 Insys Therapeutics, Inc.
March 3, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement 8-K 1 insy20150302b8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 25, 2015 INSYS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdictio
March 3, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 insy201503028k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2015 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation)
February 9, 2015	144	INSY / Insys Therapeutics Inc. 144 - - FORM 144 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
November 18, 2014	EX-99	TO JOINTLY FILE SCHEDULE 13G EX-99 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AGREEMENT TO JOINTLY FILE SCHEDULE 13G Pursuant to Rule 13d-1(k)(l) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned. Dated: August 14, 2014 /s/ John N. Kapoor JOHN N. KAPOOR JOHN N. KAPOOR TRUST, DTD 9/20/89 EJ FINANCIAL/NEO
November 18, 2014	SC 13G	INSY / Insys Therapeutics Inc. / KAPOOR JOHN N - SCHEDULE 13G Passive Investment insy20140814sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INSYS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0002145 par value per share (Title of Class of Securities) 45824V209 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
November 14, 2014	EX-99	Insys Therapeutics Reports Third Quarter 2014 Financial Results $58.3 Million in Net Revenue versus $29.2 Million in Q3 2013 Cash, Cash Equivalents, and Investments Up at the End of Quarter to $89.5 million ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Third Quarter 2014 Financial Results $58.3 Million in Net Revenue versus $29.2 Million in Q3 2013 Cash, Cash Equivalents, and Investments Up at the End of Quarter to $89.5 million PHOENIX, AZ – November 11, 2014 - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced its financial results for the three- and nine- month peri
November 14, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition insy201411138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 \ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commissi
November 14, 2014	EX-99	Insys THERAPEUTICS Moderator: Lisa Wilson November 11, 2014 10:00 am CT EX-99 3 ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Insys THERAPEUTICS Moderator: Lisa Wilson 11-11-14/10:00 am CT Confirmation # 21738685 Page 1 Insys THERAPEUTICS Moderator: Lisa Wilson November 11, 2014 10:00 am CT Woman: Master recording for reservation number 21738685 for Insys Therapeutics. Ladies and gentlemen thank you for standing by and welcome to the Insys Therapeutics Third Quarter 2013 Finan
November 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35902 I
November 12, 2014	EX-10	Employment Offer Statement effective January 31, 2014 by and between Registrant and Franc Del Fosse (16) Exhibit 10.1 INSYS THERAPEUTICS, INC. (?COMPANY?) EMPLOYMENT OFFER STATEMENT (?OFFER STATEMENT?) TO: Franc Del Fosse DATE: January 31, 2014 STATUS: Salary, Exempt START DATE: February 1, 2014 POSITION: General Counsel, which is an officer position reporting to the President and Chief Executive Officer (?CEO?). You will work at the Company?s facility in Chandler, Arizona, provided that the Company
November 10, 2014	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits 8-K 1 insy201411108k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporatio
November 10, 2014	EX-3	AMended and restated BYLAWS OF INSYS THERAPEUTICS, Inc. ARTICLE I Offices ex3-1.htm Exhibit 3.1 AMended and restated BYLAWS OF INSYS THERAPEUTICS, Inc. ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the c
October 31, 2014	8-K	Current Report insy201410318k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 27, 2014 INSYS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of Incorporatio
October 31, 2014	EX-10	Separation and Consulting Agreement ex10-1.htm Exhibit 10.1 Separation and Consulting Agreement This Separation and Consulting Agreement ("Agreement") is entered into as of October 31, 2014 (the "Execution Date") by and between Insys Therapeutics, Inc., a Delaware corporation (the "Insys"), on behalf of itself, its subsidiaries and other corporate affiliates and each of their respective employees, officers, directors, owners, shareh
October 16, 2014	EX-99	Insys Provides Update on Dronabinol Oral Solution New Drug Application ex99-1.htm Exhibit 99.1 For Immediate Release Insys Provides Update on Dronabinol Oral Solution New Drug Application PHOENIX, AZ – October 15, 2014 – Insys Therapeutics, Inc. (Nasdaq: INSY) today announced that it has received a Refusal to File Letter from the United States Food and Drug Administration (FDA) for its proprietary Dronabinol Oral Solution because it provided an inadequate or incomple
October 16, 2014	8-K	Financial Statements and Exhibits, Other Events insy201410158k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission
September 12, 2014	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission File No.) (IRS Emp
August 18, 2014	EX-4.1	Rights Agreement, dated August 15, 2014 between Insys Therapeutics, Inc. and Computershare Trust Company, N.A. (5) EX-4.1 Exhibit 4.1 RIGHTS AGREEMENT THIS RIGHTS AGREEMENT (this “Agreement”) is dated as of August 15, 2014 and is made between INSYS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., as rights agent (“Rights Agent”). RECITALS The Board of Directors of the Company (the “Board”) has authorized and declared a dividend of one preferred share purchase r
August 18, 2014	EX-3.1	Certificate of Designation of Series A Junior Participating Preferred Stock (3) EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK (Pursuant to Section 151 of the Delaware General Corporation Law) INSYS THERAPEUTICS, INC., a Delaware corporation (the “Company”), does hereby certify that pursuant to the provisions of Section 151(g) of the Delaware General Corporation Law (the “DGCL”), the Board of Directors of the Company (the “Board
August 18, 2014	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission File No.) (IRS Emplo
August 18, 2014	8-A12B	INSY / Insys Therapeutics Inc. 8-A12B - - FORM 8-A Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 51-0327886 (State of incorporation or organization) (I.R.S. Employer Identification No.) 1333 Sou
August 14, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 insy201408138k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation)
August 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35902 Insys
August 12, 2014	EX-3	Amended and Restated Certificate of Incorporation of Insys Therapeutics, Inc. (1) Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSYS THERAPEUTICS, INC. Insys Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: First: The name of this corporation is Insys Therapeutics, Inc. Second: The date of filing of its original Certificate of Incorporation with the Secretary of State of the State
August 12, 2014	EX-99	Insys Therapeutics Reports Second Quarter 2014 Results $55.7 Million in Net Revenue versus $18.8 Million in Q2 2013 Cash, Cash Equivalents, and Investments Up at the End of the Quarter to $75.3 million Pharmaceutical Cannabinoid Program Advanced with ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports Second Quarter 2014 Results $55.7 Million in Net Revenue versus $18.8 Million in Q2 2013 Cash, Cash Equivalents, and Investments Up at the End of the Quarter to $75.3 million Pharmaceutical Cannabinoid Program Advanced with Planned Submission of NDA for Dronabinol Oral Solution and Orphan Drug Designation for Two Potential In
August 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission File No.) (IRS Emplo
May 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35902 Insys
May 13, 2014	EX-99	Insys Therapeutics Reports First Quarter 2014 Results $41.6 Million in Net Revenue Marks Fifth Consecutive Quarter of Revenue Growth Three-for-Two Stock Split Increases Shares Outstanding to 34.2 Million Shares ex99-1.htm Exhibit 99.1 For Immediate Release Insys Therapeutics Reports First Quarter 2014 Results $41.6 Million in Net Revenue Marks Fifth Consecutive Quarter of Revenue Growth Three-for-Two Stock Split Increases Shares Outstanding to 34.2 Million Shares PHOENIX, AZ – May 13, 2014 - Insys Therapeutics, Inc. (NASDAQ: INSY), today announced its financial results for the three-month period ended Ma
May 13, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission File No.) (IRS Employer
May 12, 2014	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2014 Insys Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35902 51-0327886 (State of incorporation) (Commission File No.) (IRS Employer
April 15, 2014	DEF 14A	- FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant☒ Filed by a Party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☒ Definitive Proxy Stateme
April 3, 2014	PRE 14A	- FORM PRE 14A PRE 14A 1 insy20140403pre14a.htm FORM PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant☒ Filed by a Party other than the Registrant☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED B
April 1, 2014	8-K	Current Report 8-K 1 insy201404018k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 28, 2014 INSYS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35902 51-0327886 (State or Other Jurisdiction of
April 1, 2014	EX-10	Separation and Consulting Agreement ex10-1.htm Exhibit 10.1 Separation and Consulting Agreement This Separation and Consulting Agreement ("Agreement") is entered into as of March 28, 2014 (the "Execution Date") by and between Insys Therapeutics, Inc., a Delaware corporation, (the "Insys") on behalf of itself, its subsidiaries and other corporate affiliates and each of their respective employees, officers, directors, owners, sharehol

INSY / Insys Therapeutics Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)